Integra LifeSciences
IART
248 hedge funds and large institutions have $3.23B invested in Integra LifeSciences in 2018 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 92 increasing their positions, 77 reducing their positions, and 46 closing their positions.
409% more call options, than puts
Call options by funds: $1.22M | Put options by funds: $239K
19% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 77
0% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 46
0% less funds holding
Funds holding: 249 → 248 (-1)
2.86% less ownership
Funds ownership: 86.85% → 83.99% (-2.9%)
34% less capital invested
Capital invested by funds: $4.87B → $3.23B (-$1.64B)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
Top Sellers
IART Hedge Fund Activity: Q4 2018 in Review
248 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q4 2018, worth a combined $3.23B — down 34% from $4.87B a quarter earlier.
Fund positioning in IART was balanced in Q4 2018: 46 funds opened new positions, 46 closed out, 92 added to existing stakes and 77 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $117M. The largest seller was Fidelity Investments, cutting an estimated $291M.
- 248 institutional investors held Integra LifeSciences (IART) as of Q4 2018, down from 249 in Q3 2018.
- Funds reported $3.23B of Integra LifeSciences stock for Q4 2018, down 34% quarter-over-quarter.
- 46 funds opened new Integra LifeSciences positions in Q4 2018 and 46 closed out, a net change of 0 holders.
- The largest Integra LifeSciences buyer in Q4 2018 was Capital International Investors, an estimated $117M added.
- The largest Integra LifeSciences seller in Q4 2018 was Fidelity Investments, an estimated $291M sold.
Based on aggregated 13F filings for Q4 2018.